Error
  • The template for this display is not available. Please contact a Site administrator.

Sections, IGs and WGs

Wg on Immunomodulation & Nutrition

Elected board 2022-2024
Chair

Carina Venter (USA)

Secretary
Franziska Roth-Walter (Austria)

Board Members
Diego Peroni (Italy)
Roberto Berni Canani (Italy)
Emilia Vassilopoulou (Greece)

Immunonutrition involves the study of the direct and indirect effects of nutrients and foods, on immune system development, functionality, and responsiveness. It is important to understand the long-term effect of nutrients and food on chronic disease prevention and management. The recent development of “omics” and the multi-disciplinary range of EAACI members will enable our task force to advance the study of nutrition on allergic disease outcomes now and in future. In addition, we will support the education of EAACI members in best practices for nutritional considerations in optimal patient care.

The aims of this group are to bring together the expertise of dieticians, clinicians, scientists and researchers across multiple disciplines including allergy, nutrition, immunology, genetics and the microbiome to:

(i) Identify the gaps in our knowledge on the effects of nutrition, both deficiencies and excesses, on immune development and function;
(ii) Provide updated knowledge and scientifically validated advice, via position papers and conference symposia, on the use of specific nutrients in allergy prevention and treatment;
(iii) Advance the field of Immunonutrition by coordinating grant applications and research collaborations between members of the working group;
(iv) Support the education of patients and the public on the importance of dietary choices for healthy immune development, during all stages of life.

Wg on AllergoOncology

2022-2024
 

Erika Jensen JarolimFelicitas Matern

SK

MP

elenaizquierdo

aureliepoli

 
Chair
Erika Jensen-
Jarolim (Austria)
Secretary
Sophia
Karagiannis (UK)

Board Member

Mariona Pascal
Capdevila
(Spain)
Board Member
Elena Izquierdo
(Spain)
Board Member
Aurélie Poli
(Luxembourg)



 

 

 


AllergoOncology News: Transition of TaskForce into Working Group!


The WG for AllergoOncology is a hard-working group of enthusiastic academic and clinical experts in both, allergy and cancer with an innovative interdisciplinary agenda, driving novel ideas that link Allergy with several disciplines, for the benefit of patients and overall contributing to the research and translational aspirations and originality of EAACI.

The EAACI Task Force for AllergoOncology was founded in 2014 within the Basic Immunology Section to investigate the unique immunologic interface between allergy, IgE immune responses and oncology. One key area of interest stems from observations that high IgE levels in atopic individuals are associated with lower prevalence of some tumour types. Also, whilst immune tolerance is not desired in cancer, IgE-mediated immune surveillance targeted to cancer cells, might be. The world´s first clinical trial of a recombinant anti-cancer IgE ongoing in the UK is pioneered by members of the AllergoOncology group.
The most recent position paper of our group (Ferastraoaru et al., Clinical Translational Allergy 2020) for the first time presents collective evidence that, apart from roles in allergy pathology and anti-parasite immunity, especially, ultra-low IgE serum levels <2.5 kU/L could be a biomarker for a risk of developing new malignancies (17.65%). The AllergoOncology concept therefore, brings to light completely new aspects of the biological roles of IgE antibodies which are of high interest and clinical relevance.

Ongoing and planned projects

Ongoing: Position paper 5: “Danger Signals in Allergy and Oncology”.

Planned: Virtual Training day on Inflammation in Allergy and Cancer, hosted by Sophia N. Karagiannis, King´s College London, UK, in summer 2021 (date and program will be announced in short).

Planned: Virtual Business Meeting at 2021 Annual EAACI conference, Warsaw, Poland.

Planned: Position paper 6: “Letter of the allergist to the oncologist”

Reference
Ferastraoaru D, Bax HJ, Bergmann C, Capron M, Castells M, Dombrowicz D, Fiebiger E, Gould HJ, Hartmann K, Jappe U, Jordakieva G, Josephs DH, Levi-Schaffer F, Mahler V, Poli A, Rosenstreich D, Roth-Walter F, Shamji M, Steveling-Klein EH, Turner MC, Untersmayr E, Karagiannis SN & Jensen-Jarolim E. (2020). AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clin Transl. Allergy (10:32). DOI: 10.1186/s13601-020-00335-w.

AllergoOncology Position Papers

Bergmann C, Poli A, Agache I, Bianchini R, Bax HJ, , Castells M, , Crescioli S, Dombrowicz D, Ferastraoaru D, Fiebiger E, Gould HJ, Hartmann K, Jordakieva G, Josephs DH, Jutel, M, Levi-Schaffer F, Lotze MT, Osborn G, Redegeld F, Rosenstreich D, Roth-Walter F, Schmidt-Weber, CB, Shamji M, Steveling EH, Turner MC, Untersmayr E, Jensen-Jarolim E, Karagiannis SN. AllergoOncology: Danger signals in Allergology and Oncology. A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). In progress.

Ferastraoaru D, Bax HJ, Bergmann, C, Capron M, PhD, Castells M, MD Dombrowicz D, Fiebiger E, Gould HJ, Hartmann K, Jappe U, Jordakieva G, Josephs DH, Levi-Schaffer F, Mahler V, Poli A, Rosenstreich D, Roth-Walter F, Shamji M, Steveling EH, MD, Turner MC, Untersmayr E, Karagiannis N. S, Jensen-Jarolim E. AllergoOncology: Is low IgE a potential novel biomarker in cancer? A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clinical Translational Allergy, 2020 Jul 17;10:32. doi: 10.1186/s13601-020-00335-w. eCollection 2020.  https://pubmed.ncbi.nlm.nih.gov/32695309/

Untersmayr E, O´Mahony L, Roth-Walter F, Bergmann C, Turner M, Bergmann K, Redegeld F, Betty, Penichet M, Wendy, Bax H, Bianchini R, Vangelista L, Karagiannis L, Jensen-Jarolim E. AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper. Allergy, 2019 Jun;74(6):1037-1051. https://pubmed.ncbi.nlm.nih.gov/30636005/

Jensen-Jarolim E, Bax HJ, Bianchini R, Crescioli S, Daniels-Wells TR, Fazekas-Singer J, Fiebiger E, Gould HJ, Janda J, Josephs DH, Levi-Schaffer F, O´Mahony L, Pelizzari G, Penichet ML, Redegeld F, Roth-Walter F, Singer J, Untersmayr E, Vangelista L, Karagiannis SN. AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer. EAACI Position paper. Allergy. 2017 Sep 16. doi: 10.1111/all.13311. https://pubmed.ncbi.nlm.nih.gov/28921585/

Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels-Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould H, Janda J, Josephs DH, Karagiannis P, Levi-Schaffer F, Meshcheryakova A, Mechtcheriakova D, Mekori J, Mungenast F, Nigro EA, Penichet ML, Redegeld F, Saul L, Singer J, Spicer JF, Siccardi AG, Spillner E, Turner M, Untersmayr E, Vangelista L, Karagiannis SN. AllergoOncology - The impact of Allergy in Oncology. EAACI Position Paper. Allergy. 2016 Dec 29. doi: 10.1111/all.13119. https://pubmed.ncbi.nlm.nih.gov/28032353/

Jensen-Jarolim, E.,*, G. Achatz, M.C. Turner, S. Karagiannis, F. Legrand, M. Capron, M. Penichet, J.A. Rodriguez, A. Siccardi, L Vangelista, A.B. Riemer, and H. Gould. 2008. AllergoOncology: The role of IgE-mediated allergy in cancer. Allergy 63 (10): 1255-66. https://pubmed.ncbi.nlm.nih.gov/18671772/


[PHOTO SUPPLIED: CAPTION] The AllergoOncology Task Force during a workshop in Vienna (November 2019) which was dedicated to the preparation of this position paper.

AllergoOncology pic
Board 2022-2024

 

WG Chair
Elizabeth Angier

WG Secretary
Hilary Allen

Board Member
Bertine Flokstra-de Blok
Laura Losappio
Ester Seberova



Board 2019-2022

 

WG Chair
Rosan Meyer

WG Secretary
Gavriela Feketea

Board Member
Radoslaw Gawlik
Matthew Doyle
Mairead Sheehan
Audrey DunnGalvin
Berber Vlieg-Boestra

JM Representative
Farah Hannachi



Board 2022-2024


 

WG Chair
Maria Escribese

WG Secretary
Urszula Radzikowska

Board Member

I. Cagatay Karaaslan
Carlos Aranda Clemente
Chiara Tontini


Board 2022-2024


 

WG Chair
Athanasios Damialis

WG Secretary
Celia Antunes

Board Member

Roberto Albertini
Carmen Galan
Ayse Baccioglu

Board 2022-2024


 

WG Chair
Joao Rufo

WG Secretary
Thulja Trikamjee

Board Member
Joshua LawsonSemra Demir
Ekaterina Khaleva

Board 2022-2024

 
WG chair
Arantza Vega Castro

WG Secretary
Elisa Boni

Board member
Matteo Martini

Board member
Gulnar Aliyeva

Board member
Christine Breynaert
Board 2022-2024

C Hilger1

Interest Group chair
Christiane Hilger
perfil AV

Interest Group secretary
Alma Villasenor Solis

Board members
Anastasios Constantinopoulos
Stephanie Dramburg-Hofmaier
Simon Blank
Annette Kuehn
Luisa Brussino


JM Representative
Riccardo Castagnoli

 



Board 2022-2024


 

IG Chair
Constantinos Pitsios
Cyprus



IG Secretary
Carlo Maria Rossi
Italy



Past Chair
Antonella Cianferoni
USA



Board Members:

Dagmar Simon
Martina Votto
Arzu Bakirtas






-



About Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus. It may occur in all ages with characteristic symptoms of esophageal dysfunction, while diagnosis is confirmed by endoscopic findings and a significant esophageal eosinophilia. In adults, it is associated with difficulty in swallowing, food impaction, chest pain and stricture formation in the esophagus. In children, symptoms include vomiting and regurgitation, feeding disorders and oral aversion, food impaction and a general failure to thrive. Endoscopic findings that might signal eosinophilic esophagitis include rings, stricture, furrow or straight lines, white spots, and a small-caliber esophagus. However, endoscopy in patients with EoE may result without pathological findings. The etiology of EoE is not known, however atopy is a risk factor. Most patients with EoE are allergic to inhalants and food allergens. But in 30% of patients, endoscopic exams turn up normal. Treatment of EoE is mainly based on dietary restrictions and antiinflamatory medications, while endoscopical interventions are necessary in severe cases of esophageal stenosis. The EoE WG intents to inform and update EAACI members on this diseases, to offer educational tools and organize educational meetings on EoE.

 


-



Recommended Articles


Eosinophilic esophagitis is characterized by a non-IgE mediated food hypersensitivity
D Simon, et al. 
https://onlinelibrary.wiley.com/doi/full/10.1111/all.12846


Microbiome and its impact on gastrointestinal atopy

AB Muir et al. 
https://onlinelibrary.wiley.com/doi/10.1111/all.12943


Diagnosis and management of non-IgE gastrointestinal allergies in breastfed infants - an EAACI position paper
R Meyer et al. 
https://onlinelibrary.wiley.com/doi/10.1111/all.13947


Eosinophilic esophagitis phenotypes: Ready for prime time?
D Atkins et al. 
https://onlinelibrary.wiley.com/doi/10.1111/pai.12715




-



Social Media


Are you interested in receiving the latest Allergy, PAI and CTA publications about Eosiniphilic Esophagitis on social media?

Stay tuned by following us on:

Twitter - @EAACI_HQ
Facebook - @EAACI
LinkedIn -
EAACI

Instagram - EAACI

 

Board 2022-2024


 

IG Chair
Hille Suojalehto

IG Secretary
Marcela Valverde Monge

Section Past Chair
Mohamed Jeebhay

Board members

Paola Mason
Ilenia Folletti
Omur Aydin
Marta Wiszniewska
Irmeli Lindstrom


JM Representative
Magna Correia   



-



Interview with Santiago Quirce, International Hospital La Paz

 

Santiago discusses the importance of occupational asthma


“Work aggravated asthma occurs in about 20% of patients with
ashma

June 2019

 

Board 2022-2024



IG Chair
Enrico Heffler

IG Secretary
Dario Antolin-Amerigo

Past Chair
Montserrat Alvaro Lozano

Board member
Kit Liang Gan

Board member
Cristina Quecchia

Board member

Umit Murat Sahiner

Board member

Kymble Spriggs

JM Representative

Eyice Karabacak




Board 2022-2024

Annick Barbaud
IG Chair
Annick Barbaud



SEVİM BAVBEK

Board member
Sevim Bavbek

Lene Garvey

IG Secretary
Lene Heise Garvey


Tahía Fernandez

Board member
Tahia Fernandez-Duarte

Francesca Mori

Board member

Francesca Mori


Alla Nakonechna

Board member
Alla Nakonechna

Vito Sabato

Board member

Vito Sabato













JM Representative
Marina Labella Alvarez



Board 2022-2024

  Alberto Alvarez

Interest Group Chair
Alberto Alvarez-Perea
IMG 5729

Section secretary
George Konstantinou
Simona Barni1
Board member
Simona Barni
BEATRIZ MOYA EAACI1
JM representative
Beatriz Moya












 









Board member
Monserrat Alvaro Lozano


























Board 2022-2024


 

serge doan

WG Chair
Serge Doan

Diana Silva Photo

WG Secretary
Diana Silva

Vibha

Board member
Vibha Sharma


Board members

Pia Allegri

Francoise Brignole-Baudouin











Board 2022-2024


 

WG Chair
Oliver Price

Past Chair

Maia Rukhadze

WG Secretary
Valerie Bougault

Board members
Ceren Can
Joao Marques
Alp Kazancioglu



-
Board 2022-2024



leticia

Section Chair

Leticia De las Vecillas Sanchez
Spain
 

Carmen Riggioni
Past Chair
Carmen Riggioni




leticia
Allied Health & Primary Care
Farah Hannachi




 leticia
Asthma  
Cristina Boccabella

leticia
Allergen Immunotherapy IG
Deniz Eyice Karabak
                                    

mattia

Section Secretary
Mattia Giovannini


leticia
Allergy Diagnosis &
Systems Medicine IG
Riccardo Castagnoli


  leticia 
   
         
Basic & Clinical Immunology 
Rubén Fernández-Santamaria



leticia
Dermatology
Daniela Carvalho



Marina Labella
Drug Allergy IG
Marina Labella Alvarez












leticia
ENT Section
Aspasia Karavelia 


leticia
Environmental and
Occupational Allergy IG
Magna Correia

  

 leticia                              

Food Allergy IG
Beatriz Moya

leticia
Pediatrics  
Ekaterina Khaleva



                           




                                      


-



EAACI Journals Collaborations


The aim of the project is the dissemination of Allergy, CTA and PAI papers, especially through Social Medial (SoMe) channels (Twitter; Facebook; LinkedIn) to increase their visibility among JMs. The most interesting and recent pieces are selected as JM must read articles every month.ful sharing of knowledge between young and senior clinicians and scientists, outlining a practical overview regarding this ongoing pandemic.

JM must read articles from Allergy: find them here.

JM must read articles from PAI: find them here.

JM must read articles from CTA: the articles will be availale shortly.


 

-



JM Compendium Answering 150 questions on SARS-CoV-2 and COVID-19

JMA has created a compendium answering 150 questions on SARS-CoV-2 and COVID-19 in collaboration with an international panel of experts in the allergy and immunology field. It represents a fruitful sharing of knowledge between young and senior clinicians and scientists, outlining a practical overview regarding this ongoing pandemic.

For more information, access the full article published in the Allergy journal: doi.org/10.1111/all.14449

Anyone is welcome to join this initiative, asking additional questions on the topic.

Please send us an email at juniormembers@eaaci.org. We will be glad to receive your feedback!!!



-


JM News Corner

The JM News Corner in the Allergy webpage is is a platform where relevant items of news are periodically posted, mainly related to JMs’ achievements, projects and publications.

We would like to know more about allergy centres all around the world. Please send us a short issue about your clinical and research activities with the description of your workplace (maximum 200 words) and 2-3 high-resolution images of the place, yourself, and your team. We will be glad to share your experience with all the JMs’ community.

jma logo new

Contact us at juniormembers@eaaci.org.


Click here to keep up to date with the latest news!




-


JM Quizz

Participate in the EAACI Junior Member Quiz to have an opportunity to win a free registration for the EAACI Annual Congress 2021.


Each year the JMA board launches a quiz on the EAACI website, which will be posted each month from January to April, in order to test Juniors Member´s scientific knowledge and EAACI- related information. Each quiz consists of 5 single or multiple-choice questions.



Every month, a quiz winner will be selected, with the exception of the April quiz, where two lucky winners will be awarded!


Click below to access the Quiz:
QUIZ


-



Groundbreaking Discoveries in Immunology

This is a new section of Allergy in which brief summaries of the most innovative and relevant articles, published in Top-tier journals, are collected. The section is monthly updated. Find it on the Allergy website.



-



Educational initiatives

Build your professional career into the Allergology field!


  • Allergy College

EAACI is doing a tremendous effort to promote education on Allergology among students and fellows around Europe.

The Allergy College program gives to undergraduate students the possibility to collaborate with Mentors, selected for their prominent expertise. All the mentor-student pairs will be invited to submit an abstract on a specific subject, case report or other relevant content in this field. The best abstracts will be selected, and their corresponding students will be invited to the Annual Congress.

For further information, please send an email at juniormembers@eaaci.org.



  • Mentorship Program

One important EAACI strategic goal is to help  JMs in taking their first steps as allergy and immunology specialists.

Giving this, the Mentorship program promotes research training opportunities and encourages JMs in submitting a proposal for a manuscript, in collaboration with experienced Mentors. The best manuscripts will be proposed as a possible publication to the Editors of PAI and CTA. Furthermore, the JM Assembly will support the successful pairs, through collection of scientific contributions for the EAACI Journal or newsletter.

For further information, email us at mp@eaaci.org.

Board 2019-2022


  Section Chair
Rosan Meyer
United Kingdom

Section Secretary
Gavriela Feketea

Board members

Radoslaw Gawlik
Matthew Doyle
Mairead Sheehan
Audrey DunnGalvin
Berber Vlieg-Boerstra

JM Representative
Farah Hannachi



-



Interview with Berber Vlieg-Boestra, Hanze University

 

Berber Vlieg highlights the important role of dietitians in the
diagnosis and management of allergic diseases



(Allied Health Professionals) collaborate in a multidisciplinary
team to give the best treatment to the patient"

June 2019

ENT1


Board 2022-2024


 
Section Chair

Sanna Toppila-Salmi
Finland

Section Secretary
Valerie Hox

Section Past Chair
Ludger Klimek

Board members
Valerie Hox
Adam Chaker
Juan Maza Solano
Sietze Reitsma
Rudenko
Simon Gane

JM Representative
Aspasia Karavelia

 


-



Interview with Philippe Gevaert, Ghent University

 

Philippe Gevaert talks about the importance of interaction
between ENT specialists and immunotherapy and biologics
specialists, and highlights the importance of understanding
who to treat with these medications.



”It is crucial to take a good product for the right patient and to
tailor it for the patient itself. Precision medicine (...) is about
combining the needs of the patient"

June 2019

 









-









-


Recommended reads


Auge et al - EAACI position paper on standardization of nasal allergen challenges

Roberts et al - EAACI Guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis

Hellings et al - Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology

Hellings et al - Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUROREA-ARIA-EPOS-AIRWAYS ICP statement

Pfaar et al - Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI position paper

 

Board 2022-2024


 



Section Chair

Jose Luis
Garcia-Abujeta



Section Past Chair
Charlotte Mortz
Denmark

Section Secretary
Maria Bova

Board members

Maria Bova
Barbara Ballmer-Weber
Annalisa Santucci
Elena Petkova
Pavel Kolkhir
Leonie Herzog

JM Representative
Daniela Carvalho



-



Interview with Charlotte Mortz, Odense Hospital University, and Knut Brockow, Munich Technical University

 

Charlotte Mortz and Knut Brockow discuss the importance and
prevalence of skin allergy



“Between 20-30% of the population has had skin allergy at
some point in their lives (...) A disease like atopic dermatitis
affects 20% of all children at some point in their childhood

June 2019

 





 

Peter Schmid-Grendelmeier discusses the biggest challenges
in allergic skin diseases and highlights European priorities in
the field



“"In the field of allergic skin diseases (there is) an increase of
atopic dermatitis, which is a global problem, (...) and a rapid
increase in some contact allergens that cause contact
dermatitis"

June 2019

 

Board 2022-2024


 

Stefania

Section Chair
Stefania Arasi
Italy

sophia

Section Secretary
Sophia Tsabouri
Greece

Helen Brough - EAACI Pediatrics Section Chair

Section Past Chair

Helen Brough
United Kingdom

Marta Pediatric

Board Member
Marta Vazquez-Ortiz
Spain

Burcin

Board Member
Beken Burcin
Turkey

 

Luis Moral

Board Member
Luis Moral

Spain

Wojtek Feleszko

Board member

Wojciech Feleszco
Poland

Carmen_Riggioni.jpg

Board Member

Carmen Riggioni Viquez
Singapore

Kate Khaleva

JM Representative

Ekaterina Khaleva
United Kingdom





-


Interview with Montserrat Alvaro Lozano, Barcelona University

 

Montserrat Alvaro Lozano discusses the status of food allergy
and immunotherapy in pediatrics



“"There are many food allergic children who have the risk of
anaphylaxis (...) so we must find a solution

June 2019




















-


Section reports

Pediatric section report July 2020

-


Training and certifications in Pediatric Allergology



Please find here more information on: 

European accreditation of Pediatric Allergology Training Centres

Certification as European Specialist in Pediatric Allergology


-

Task Forces

Food immunotherapy practice in Europe (FIND project)
Food allergy is a worldwide pandemic where the standard treatment is limited to avoidance or rescue medication in cases of accidental exposure. In the last decade, scientists developed a promising treatment called food immunotherapy. This is the first food allergy treatment that ameliorates the reactions´ severity or in some cases even allows the patient to incorporate the culprit food into his/her diet. However, this treatment is still being researched and is only being used regularly in some European countries. EAACI believes it should be used in highly specialized centres for daily care across Europe. Therefore, this task force aims to analyse the countries where food immunotherapy is becoming a standard treatment to provide a comprehensive recommendation in terms of facilities, patient selection and treatment characteristics to other countries. The goal is to provide a solid recommendation basis to facilitate the implementation of food immunotherapy as a treatment across Europe.


Chair: Pablo Rodriguez del Rio
Secretary: Montserrat Alvaro


-

Allergic diseases in adolescents and young people
Although adolescents and young people are regarded as a healthy age group, death rates due to food allergy reactions and asthma are highest at this age. Furthermore, healthcare resources are not focused on this age group although this is a critical period for the development of allergic diseases. Besides being life threatening, allergic diseases such as allergic rhinitis and atopic dermatitis can impair work and school performances and negatively impact quality of life, self-esteem and identity in young people.
The aim of this task force is to focus on this age group and seek to determine the particular features of these allergic diseases, including their challenges, specific needs and efficient management strategies. This will allow the task force to produce clear recommendations to optimise healthcare for this critical age, as well as to identify unmet needs and pinpoint further required efforts in the field.

Chair: Graham Roberts
Secretary: Marta Vazquez Ortiz


-


Clinical outcomes of efficacy in food allergen immunotherapy trials
Food allergy represents a prevalent disease, affecting around 8% of European children and 2-5% of adults. Standard treatment is based upon avoidance and the use of rescue medication in case of accidental exposure to the trigger. For the last decades, but especially in the last 10 years, important advances have been made in order to provide an etiological treatment to treat this disease. All these treatments, so called food immunotherapy, aim first at protecting the patient by increasing his/her reactivity threshold, and in some cases, patients are even allowed to introduce these foods (mostly milk, egg and peanut) freely in their diets. All these advances are being achieved thanks to the effort of both Academia and Industry by conducting large food immunotherapy trials to provide evidence of its efficacy. However, the way efficacy is measured significantly varies from study to study, limiting the chances to make direct comparisons, and thus, potentially selecting the most suitable for each candidate in the future if these become available.

The aim of the current task force is to evaluate all clinical variables of efficacy used in food immunotherapy trials, and try to make recommendations on the convenience of using each of them. Eventually, the team might be able to make recommendations for the selection of this variables in future immunotherapy trials.

Chair: Pablo Rodriguez del Rio
Secretary: Montserrat Fernandez Rivas


-

Targeting the skin barrier in atopic dermatitis
There is a strong need to identify new management approaches for the prevention of atopic dermatitis (AD), due to its substantial burden on patients’ quality of life and health-care resources. In addition, AD is associated with higher risk of developing other atopic diseases. Increasing evidence suggests that skin barrier abnormalities play an essential role in initiation of early AD. The difficulties to target the underlying immune dysregulation, put forward the potential for early interventional approaches targeting skin repair. The aim of this task 
force is to provide evidence on whether the daily use of topical treatments soon after birth (before the onset of AD) and for the first months of life could reduce the occurrence of AD and/or its severity, thus representing a low cost, easy to apply, safe and effective approach for the primary prevention of AD and atopic march, at least in some phenotypes.

Chair: Elena Galli
Secretary: Pasquale Comberiati


-

Chronic urticaria in children
Chronic Urticaria in Children (CU-Kids) Task Force: we are establishing a research and clinical network for the optimal, evidence-based diagnosis and management of CU in children. This is taskforce is led by the paediatric section and clinicians who see children with CU. We comprise several relevant stakeholders from dermatology, allergy, primary care, research, immunology, epidemiology, pharmacology, biologicals prescribers, the junior section, patient representation and (through clinical networking, specialist nurses and a pharmacist). We have begun to:
identify clinical centres and colleagues who treat children with urticaria, including attendance at CU focus meetings nationally and internationally. Increase the expertise of participants for research and talks on CU in children, especially with regards to difficult to manage CU and the use of biologicals in the younger age groups:
- several members of the taskforce are involved in clinical audit and service improvement work, and new research involving the medical and supportive management of children with CU across Europe
- develop on the online survey of current clinical practice, needs and recommendations to formulate a report
- plan an EAACI position paper on CU in children for the next taskforce application

Chair: Sophia Tsabouri
Secretary: Tabi Leslie


 

Perceptions, Beliefs, Attitudes, and Decision making in parents of children with allergic diseases (PARANOID)
The aim of the task force is to assess worries and beliefs, anxiety, allergic diseases perception, medical trust/mistrust and compliance among the parents of allergic children residing in different European countries and to study factors impacting above mentioned outcomes with a particular focus on internet social networks.

Chair: Daniel Munblit
Secretary: Mary Jan Marchisotto

 

Public Outreach: scoping the needs and developing video resources for the public
The objectives of this task force is to improve awareness of what patients and the public want to know, to obtain qualitative and quantitative assessment of the value of interactive models during the clinical village, and to develop educational material for the online media library and patient portal.

Chair: Helen Brough
Secretary: Eva Untersmayr

Board 2022-2024

 

WG Chair
Thomas Eiwegger

WG Secretary
Alessandra Vultaggio


Board members
Davide Firinu
Saar Nederveen-Bendien
Gulfem Celik

Board 2022-2024


Section chair
Ibon Eguíluz-Gracia






Section past chair
Matteo Bonini
Section secretary
Andre Moreira

Board member
Ignacio Davila
Cristiano Caruso
Ian Adcock
Amelia Licari
Alina Gherasim

JM Representative
Cristina Boccabella



-


Interview with Zuzana Diamant, Lund University

 

Zuzana Diamant speaks about the current challenges in ashma and how EAACI Task Forces work in multidisciplinary effort to solve these challenges

”(the current challenges in asthma are) how to implement biologics and biomarkers and other strategic approaches, called precision medicine, into the clinical practice"
June 2019

 

Board 2022-2024

 

WG Chair
Francesco Cinetto

WG Secretary
Federica Pulvirenti

Past Chair 2019-2022
Anna Sediva


Board members
Zita Chovancova
Laia Alsina
Ayca Kiykim


Board 2022-2024

 

Section chair
Milena Sokolowska


Section past chair
Eva Untersmayr-Elsenhuber
Section secretary
Inge Kortekaas Krohn

Board members
Cristina Gomez-Casado
Cristobalina Mayorga
Alexandra Santos
Marina Perez-Gordo
Matthew Burgess


JM Representative
Rubén Fernández-Santamaría


-


Interview with Jürgen Schwarze, Edinburgh University


    

Jürgen Schwarze explains how and which viral infections
“Severe respiratory viral infections, in early-life (…), convey a much higher risk of developing asthma.”
June 2019

 

The EAACI Working Groups are established as part of the Interest Groups or Sections. Each chair of the Working Group sits automatically as an additional board member in their respective Interest Group or Section board. The EAACI Working Groups represent relevant and growing scientific areas for the academy and have a clear link or common interest to their Interest Group or Sections.

{tab=Sections}
EAACI Sections category tree
{tab=Interest Groups}
EAACI IGs category tree